<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622788</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0221</org_study_id>
    <secondary_id>NCI-2018-01557</secondary_id>
    <secondary_id>2018-0221</secondary_id>
    <nct_id>NCT03622788</nct_id>
  </id_info>
  <brief_title>Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant</brief_title>
  <official_title>Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies how well cytokine-treated veto cells work in treating patients&#xD;
      with hematologic malignancies following stem cell transplant. Giving chemotherapy and&#xD;
      total-body irradiation before a stem cell transplant helps stop the growth of cells in the&#xD;
      bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the&#xD;
      healthy stem cells from a donor are infused into the patient, they may help the patient's&#xD;
      bone marrow make stem cells, red blood cells, white blood cells, and platelets.&#xD;
      Cytokine-treated veto cells may help the transplanted donor cells to develop and grow in&#xD;
      recipients without causing graft-versus-host-disease (GVHD - when transplanted donor tissue&#xD;
      attacks the tissues of the recipient's body).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the optimal dose of anti-viral veto cells, defined as the dose which achieves&#xD;
      engraftment without severe graft-vs-host disease (GVHD) at 42 days after non-myeloablative&#xD;
      megadose T cell depleted haploidentical hematopoietic cell transplantation (HCT).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Toxicity. II. Response rate. III. Time to progression. IV. Infections. V. Immune&#xD;
      reconstitution. VI. Overall survival up to 1 year.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of cytokine-treated veto cells.&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive anti-thymocyte globulin (ATG) intravenously (IV) over&#xD;
      4 hours on days -9 to -7 and fludarabine IV over 1 hour on days -6 to -3, then undergo total&#xD;
      body irradiation (TBI) on day -1.&#xD;
&#xD;
      TRANSPLANT: Patients undergo peripheral blood stem cell transplantation (PBSCT) IV over 30-60&#xD;
      minutes on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days +3 and +4 and&#xD;
      cytokine-treated veto cells IV over 30-60 minutes on day +7.&#xD;
&#xD;
      After completion of stem cell transplant, patients are followed up once a week for 4 weeks,&#xD;
      once a month for 3 months, and then periodically for one year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal dose of donor-derived cytokine-treated veto cells</measure>
    <time_frame>Within 42 days of cytokine-treated veto cell infusion</time_frame>
    <description>For the purpose of dose-finding, toxicity is defined as steroid resistant grade 3 or 4 graft-versus-host-disease (GVHD), or death from any cause, within 42 days of veto cell infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of veto cells</measure>
    <time_frame>At day 42 post cytokine-treated veto cell infusion</time_frame>
    <description>Efficacy is defined as the patient being alive and engrafted at day 42 post veto cell infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Unadjusted distributions of time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and veto cell dose level will be evaluated by Bayesian piecewise exponential survival regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Unadjusted distributions of time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and veto cell dose level will be evaluated by Bayesian piecewise exponential survival regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Unadjusted distributions of time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and veto cell dose level will be evaluated by Bayesian piecewise exponential survival regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Unadjusted distributions of time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and veto cell dose level will be evaluated by Bayesian piecewise exponential survival regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Unadjusted distributions of time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and veto cell dose level will be evaluated by Bayesian piecewise exponential survival regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Unadjusted distributions of time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and veto cell dose level will be evaluated by Bayesian piecewise exponential survival regression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Bone Marrow Failure</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive ATG IV over 4 hours on days -9 to -7, and fludarabine IV over 1 hour on days -6 to -3, then undergo TBI on day -1.&#xD;
TRANSPLANT: Patients undergo PBSCT IV over 30-60 minutes on day 0.&#xD;
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days +3 and +4 and cytokine-treated veto cells IV over 30-60 minutes on day +7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cytokine-treated Veto Cells</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)</arm_group_label>
    <other_name>Activated Veto Cells</other_name>
    <other_name>Activated Veto T-cells</other_name>
    <other_name>Veto CD8-positive T-cells</other_name>
    <other_name>Veto Cell</other_name>
    <other_name>Veto Cells</other_name>
    <other_name>Veto-enhanced CTL</other_name>
    <other_name>Veto-enhanced Cytotoxic T-cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo PBSCT</description>
    <arm_group_label>Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>PERIPHERAL BLOOD STEM CELL TRANSPLANT</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)</arm_group_label>
    <other_name>SCT_TBI</other_name>
    <other_name>TBI</other_name>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 12-75 years. The first 3 subjects will be 18 years of age to gain experience and&#xD;
             observe safety. After 3 adult subjects have successfully engrafted and if the safety&#xD;
             profile is tolerable, adolescents age 12 may be enrolled on to the trial&#xD;
&#xD;
          -  Patients with a diagnosis either follicular lymphoma (FL), mantle cell lymphoma (MCL),&#xD;
             chronic lymphocytic leukemia (CLL), multiple myeloma (MM), Hodgkin's lymphoma (HL),&#xD;
             non-Hodgkin's lymphoma (NHL), chronic myeloid leukemia (CML), myelodysplastic&#xD;
             syndrome, myeloproliferative syndromes (MPD), acute myeloid leukemia (AML) or acute&#xD;
             lymphoid leukemia (ALL).&#xD;
&#xD;
          -  Patients with aplastic anemia and severe immune deficiency or nonmalignant bone marrow&#xD;
             failure states. Patients with severe thalassemia requiring regular blood transfusions&#xD;
             or sickle cell disease with severe clinical features (these include any clinically&#xD;
             significant sickle genotype, for example, hemoglobin SS (Hb SS), hemoglobin SC (Hb&#xD;
             SC), hemoglobin S beta thalassemia (Hb Sbeta), or Hemoglobin S-OArab genotype] with at&#xD;
             least one of the following manifestations:&#xD;
&#xD;
               -  Clinically significant neurologic event (stroke) or neurological deficit lasting&#xD;
                  &gt; 24 hours;&#xD;
&#xD;
               -  History of two or more episodes of acute chest syndrome (ACS) in the 2-year&#xD;
                  period preceding enrollment or referral despite adequate supportive care measures&#xD;
                  (i.e. asthma therapy);&#xD;
&#xD;
               -  An average of three or more pain crises per year in the 2-year period preceding&#xD;
                  enrollment or referral (required intravenous pain management in the outpatient or&#xD;
                  inpatient hospital setting);&#xD;
&#xD;
               -  Administration of regular red blood cell (RBC) transfusion therapy, defined as 8&#xD;
                  or more transfusion events per year (in the 12 months before enrollment) to&#xD;
                  prevent vaso-occlusive clinical complications (i.e. pain, stroke, or acute chest&#xD;
                  syndrome);&#xD;
&#xD;
               -  An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity &gt;=&#xD;
                  2.7 m/sec.&#xD;
&#xD;
               -  Ongoing high impact1 chronic pain on a majority of days per month for &gt;= 6 months&#xD;
                  as defined as ONE or more of the following: Chronic pain without contributory&#xD;
                  sickle cell disease (SCD) complications2, OR mixed pain type in which chronic&#xD;
                  pain is occurring at site(s) (arms, back, chest, or abdominal pain) unrelated to&#xD;
                  any sites associated with contributory SCD complications2 (e.g. leg ulcers and/or&#xD;
                  avascular necrosis)&#xD;
&#xD;
          -  Patients with hematological malignancies must have had persistent or progressive&#xD;
             disease despite initial chemotherapy and must have achieved stable disease or a&#xD;
             partial or complete response to their most recent chemotherapy. Patients with low bulk&#xD;
             or indolent relapse are eligible without additional treatment. Patients with high risk&#xD;
             acute myeloid leukemia by European LeukemiaNet (ELN) criteria in first remission are&#xD;
             eligible.&#xD;
&#xD;
          -  Availability of a haploidentical related donor.&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 70%.&#xD;
&#xD;
          -  Left ventricular ejection fraction of at least 40%.&#xD;
&#xD;
          -  Pulmonary function test (PFT) demonstrating an adjusted diffusion capacity of least&#xD;
             50% predicted value for hemoglobin concentration.&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dl.&#xD;
&#xD;
          -  Serum glutamic-pyruvic transaminase (SGPT) =&lt; 200 IU/ml.&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dl (unless Gilbert's syndrome).&#xD;
&#xD;
          -  Negative pregnancy test in a woman with child bearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Human immune deficiency virus (HIV) seropositive.&#xD;
&#xD;
          -  Uncontrolled infection or serious medical or psychiatric condition that would limit&#xD;
             tolerance to the protocol treatment.&#xD;
&#xD;
          -  Active central nervous system (CNS) malignancy.&#xD;
&#xD;
          -  Availability of medically eligible, human leukocyte antigen (HLA)-matched related stem&#xD;
             cell donor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E Champlin</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard E. Champlin</last_name>
      <phone>713-792-3618</phone>
      <email>rchampli@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Richard E. Champlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

